Selected staff and leaders listed by the company. Checked Oct 12, 2026 · Next source review Nov 11, 2026.
David A. Ricks
Chair and Chief Executive Officer, Eli Lilly and Company Company staff · Official source ↗
Lucas Montarce
Executive Vice President and Chief Financial Officer, Eli Lilly and Company Company staff · Official source ↗
Eric Dozier
Executive Vice President and Chief People Officer, Eli Lilly and Company Company staff · Official source ↗
Diogo Rau
Executive Vice President and Chief Information and Digital Officer, Eli Lilly and Company Company staff · Official source ↗
Workforce
Company-wide headcount
Approximately 50,000 employees worldwide · Worldwide employees As of Dec 31, 2025 · Checked Oct 11, 2026 · Next source review Jan 9, 2027 · Source ↗
Indiana headcount
Not yet publicly verified
Scope and reporting notes
Annual count is worldwide, including approximately 27,000 outside the United States; it is not an Indiana count.
No newer employee-only global count was established in the reviewed official sources.
Company-wide, Indiana, local and parent figures are shown separately. Reporting dates may be older than the date checked. Unavailable figures remain unverified.
Eli Lilly and Company reported that an indirect treatment comparison using ACHIEVE-3 and PIONEER PLUS data found Foundayo (orforglipron) 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction versus oral semaglutide 25 mg at 52 weeks. Presented at the 62nd EASD meeting in Milan, Lilly said analyses adjusted for covariates and that alternative statistical methods produced consistent results, supporting Foundayo's efficacy in adults with type 2 diabetes, according to the company.
Eli Lilly and Company announced Phase 3 TRIUMPH-2 results showing retatrutide delivered substantial weight loss and A1C reductions in adults with type 2 diabetes and obesity or overweight. At 80 weeks, retatrutide 12 mg produced an average 49.6 lb (20.8%) weight loss (up to 60.8 lb/23.4% for baseline BMI ≥35), and A1C reductions up to 1.6% with as many as 40.0% reaching A1C <5.7%. Lilly said it plans a BLA submission in Q1 2027.
Eli Lilly and Company reported that a new indirect treatment comparison—presented at the 62nd EASD meeting and drawing on SURMOUNT-1 and STEP UP trial data—found Zepbound (tirzepatide) 15 mg was associated with 4.5% greater mean weight loss than Wegovy HD (semaglutide 7.2 mg) at 72 weeks. Lilly also reported that participants on Zepbound 15 mg were more than three times as likely to achieve at least 20% body-weight reduction versus Wegovy HD in this analysis.
Eli Lilly and Company reported Phase 3 TRIUMPH-2 results showing that retatrutide produced substantial weight loss and A1C reductions in adults with type 2 diabetes and obesity or overweight. At 80 weeks, retatrutide 12 mg averaged 49.6 lbs (20.8%) weight loss overall and up to 60.8 lbs (23.4%) for participants with baseline BMI ≥35. A1C fell by up to 1.6%, with up to 40.0% of participants reaching A1C <5.7%. Lilly plans to submit a BLA in Q1 2027.
